Compare VSTM & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSTM | KMDA |
|---|---|---|
| Founded | 2010 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.7M | 488.6M |
| IPO Year | 2011 | 2013 |
| Metric | VSTM | KMDA |
|---|---|---|
| Price | $6.14 | $8.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $16.50 | $14.00 |
| AVG Volume (30 Days) | ★ 2.1M | 61.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 2.96% |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,914,000.00 | N/A |
| Revenue This Year | $282.64 | $13.94 |
| Revenue Next Year | $72.25 | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | ★ 209.14 | N/A |
| 52 Week Low | $4.01 | $6.29 |
| 52 Week High | $11.25 | $9.35 |
| Indicator | VSTM | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 48.73 |
| Support Level | $6.01 | $8.38 |
| Resistance Level | $6.79 | $8.88 |
| Average True Range (ATR) | 0.39 | 0.19 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 97.40 | 72.22 |
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.